CF PharmTech, Inc. (HKG:2989)

Hong Kong · Delayed Price · Currency is HKD

17.51

0.00 (0.00%)

At close: Jul 31, 2026

Market Cap	8.16B
Revenue (ttm)	481.31M +23.9%
Net Income	2.77M
EPS	0.01
Shares Out	n/a
PE Ratio	2,950.19
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	17.51
Day's Range	n/a
52-Week Range	17.51 - 17.51
Beta	1.07
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs and other related medical products in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of ... [Read more]

Industry Pharmaceutical Preparations

Founded 2007

Employees 540

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2989

Financial Performance

In 2025, CF PharmTech's revenue was 432.52 million, a decrease of -28.83% compared to the previous year's 607.75 million. Earnings were 2.49 million, a decrease of -88.22%.

Financial numbers in CNY Financial Statements